Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: This spontaneous report as heard from the radio news refers to a 13 year old female patient. In November 2013 (also reported therapy stop date as 16-OCT-2014) the patient was vaccinated with the first dose of GARDASIL intramusuclarly (dose and lot number not reported). Strength was reported as "2 doses". On an unknown date, the patient received her second dose of GARDASIL, intramuscularly (dose and lot number not reported). After the second dose, the patient referred vertigo and leg weakness. In January 2014 (reported as January) the symptoms got worse generating walking difficulties. The patient improved her condition after medical attention in the hospital. Magnetic resonance imaging (MRI) was performed and spine injuries associated to the presence of lead in blood were identified. According to the diagnosis provided by the physicians, blood test was performed to identify heavy metals, with positive results for lead. Chelation treatment was started, with improvements in the symptoms. In addition, physical therapy was started. On an unknown date the patient also experienced legs pain and dizziness. At the time of the report, the patient was incapacitated. Upon internal review, the events vertigo, leg weakness, walking difficulties, spinal injury and lead in blood were considered to be disabling. The outcome of spinal injuries associated to the presence of lead in blood, presence of lead in blood, walking difficulties, leg weakness and vertigo was recovering/resolving (also reported as unknown). The outcome of leg pain and dizziness is unknown. The relatedness between therapy with GARDASIL and adverse events was not reported. Additional information has been requested.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166